Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29529712 | 1.00 | EGLN2 (0.47) | EGLN2HDAC4HDAC6CYP17A1ATR | |
| SCHEMBL24003976 | 0.92 | SYK (0.48) | EGLN2HDAC4HDAC6CYP17A1MALT1 | |
| SCHEMBL29675506 | 0.82 | CYP17A1 (0.43) | EGLN2CYP17A1ATRNAMPTMAP4K4 | |
| SCHEMBL19077885 | 0.82 | CYP17A1 (0.43) | EGLN2CYP17A1ATRNAMPTMAP4K4 | |
| SCHEMBL15774266 | 0.81 | GSK3B (0.45) | EGLN2CYP17A1KDRCA12CA1 | |
| SCHEMBL1501665 | 0.80 | SMARCA2 (0.57) | CYP17A1ATRCA12CA1CA9 | |
| SCHEMBL30293080 | 0.80 | SMARCA2 (0.57) | HDAC6CYP17A1ATRCA12CA1 | |
| SCHEMBL16055308 | 0.80 | SMARCA2 (0.57) | HDAC6CYP17A1ATRCA12CA1 | |
| SCHEMBL11615612 | 0.79 | ALDH1A1 (0.48) | EGLN2HDAC4HDAC6MALT1JAK2 | |
| SCHEMBL6452120 | 0.79 | AR (0.59) | EGLN2CYP17A1JAK2JAK1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118164961-A | 4-Methylsulfonyl substituted piperidine urea compounds for the treatment of Dilated Cardiomyopathy (DCM) | 迈奥卡迪亚公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-111393414-B | 4-Methylsulfonyl substituted piperidine urea compounds for the treatment of Dilated Cardiomyopathy (DCM) | 迈奥卡迪亚公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-3247707-B1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS USEFUL FOR THE TREATMENT OF CARDIAC DISORDERS SUCH AS DILATED CARDIOMYOPATHY (DCM) | MYOKARDIA INC (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220117955-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | MyoKardia, Inc. | 2022-04-21 | — | — | US | disclosed |
| US-11123337-B2 | 4-methylsulfonyl-substituted piperidine urea compounds | MyoKardia, Inc. (US) | 2021-09-21 | — | — | US | disclosed |
| WO-2020230136-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2020-11-19 | — | — | WO | disclosed |
| US-20200345716-A1 | 4-Methylsulfonyl-Substituted Piperidine Urea Compounds | MyoKardia, Inc. | 2020-11-05 | — | — | US | disclosed |
| US-10758525-B2 | 4-methylsulfonyl-substituted piperidine urea compounds | MyoKardia, Inc. (US) | 2020-09-01 | — | — | US | disclosed |
| CN-111393414-A | 4-methylsulfonyl substituted piperidine urea compounds for the treatment of Dilated Cardiomyopathy (DCM) | 迈奥卡迪亚公司 | 2020-07-10 | — | — | CN | disclosed |
| US-20200113887-A9 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | MyoKardia, Inc. | 2020-04-16 | — | — | US | disclosed |
| WO-2016118774-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS FOR THE TREATMENT OF DILATED CARDIOMYOPATHY (DCM) | MyoKardia, Inc. (US) | 2016-07-28 | — | — | WO | disclosed |
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| EP-1122242-B1 | CYANOPHENYL DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2008-01-16 | — | — | EP | disclosed |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-1424336-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
| US-20040010037-A1 | Cyanophenyl derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. | 2004-01-15 | — | — | US | disclosed |
| US-6673799-B1 | INHIBITS BINDING TO ANDROGEN RECEPTOR; ANTIANDROGEN | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-01-06 | — | — | US | disclosed |
| EP-1122242-A1 | CYANOPHENYL DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010037-A1 | Cyanophenyl derivative | BPHL, AR, KLK3 | EGLN2 237/4885HDAC4 119/4885HDAC6 417/4885 |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | MIF, MORF4L1, FOXM1 | EGLN2 2794/4885HDAC4 987/4885HDAC6 623/4885 |
| US-20200113887-A9 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | TNNI3, UMPS, TNNT2 | EGLN2 624/4885HDAC4 196/4885HDAC6 1100/4885 |
| US-20220117955-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | TNNI3, UMPS, TNNT2 | EGLN2 624/4885HDAC4 196/4885HDAC6 1100/4885 |
| US-10758525-B2 | 4-methylsulfonyl-substituted piperidine urea compounds | TNNI3, UMPS, TNNT2 | EGLN2 624/4885HDAC4 196/4885HDAC6 1100/4885 |
| US-20200345716-A1 | 4-Methylsulfonyl-Substituted Piperidine Urea Compounds | TNNI3, UMPS, TNNT2 | EGLN2 624/4885HDAC4 196/4885HDAC6 1100/4885 |
| US-11123337-B2 | 4-methylsulfonyl-substituted piperidine urea compounds | TNNI3, UMPS, TNNT2 | EGLN2 624/4885HDAC4 196/4885HDAC6 1100/4885 |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | MIF, MORF4L1, FOXM1 | EGLN2 2794/4885HDAC4 987/4885HDAC6 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.